1-20 of 494
daratumumab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing

Elisabeth Ehrend, Patricia Manns, Sabine Harenkamp, Erhard Seifried, Christof Geisen, Halvard Bonig
Journal: Blood
Blood (2021) 138 (9): 814–817.
https://doi.org/10.1182/blood.2021011396
Published: 2021
Includes: Supplemental data
Journal Articles

Daratumumab in transplant regimens for myeloma?

Clinical Trials & Observations
Jean Luc Harousseau, Mohamad Mohty
Journal: Blood
Blood (2020) 136 (8): 917–918.
https://doi.org/10.1182/blood.2020006298
Published: 2020
Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Clinical Trials & Observations
Peter M. Voorhees, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Jr, Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S. Lin, Paul G. Richardson
Journal: Blood
Blood (2020) 136 (8): 936–945.
https://doi.org/10.1182/blood.2020005288
Published: 2020
Includes: Supplemental data
Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Clinical Trials & Observations
Giovanni Palladini, Efstathios Kastritis, Mathew S. Maurer, Jeffrey Zonder, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, Hans C. Lee, Naresh Bumma, Jonathan L. Kaufman, Eva Medvedova, Tibor Kovacsovics, Michael Rosenzweig, Vaishali Sanchorawala, Xiang Qin, Sandra Y. Vasey, Brendan M. Weiss, Jessica Vermeulen, Giampaolo Merlini, Raymond L. Comenzo
Journal: Blood
Blood (2020) 136 (1): 71–80.
https://doi.org/10.1182/blood.2019004460
Published: 2020
Includes: Supplemental data
Journal Articles

AL patients don’t dare go without dara

Clinical Trials & Observations
Angela Dispenzieri
Journal: Blood
Blood (2020) 135 (18): 1509–1510.
https://doi.org/10.1182/blood.2020005436
Published: 2020
Journal Articles

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

Clinical Trials & Observations
Vaishali Sanchorawala, Shayna Sarosiek, Amanda Schulman, Meredith Mistark, Mary Ellen Migre, Ramon Cruz, J. Mark Sloan, Dina Brauneis, Anthony C. Shelton
Journal: Blood
Blood (2020) 135 (18): 1541–1547.
https://doi.org/10.1182/blood.2019004436
Published: 2020
Journal Articles

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Clinical Trials & Observations
Murielle Roussel, Giampaolo Merlini, Sylvie Chevret, Bertrand Arnulf, Anne Marie Stoppa, Aurore Perrot, Giovanni Palladini, Lionel Karlin, Bruno Royer, Antoine Huart, Margaret Macro, Pierre Morel, Laurent Frenzel, Cyrille Touzeau, Eileen Boyle, Véronique Dorvaux, Fabien Le Bras, David Lavergne, Frank Bridoux, Arnaud Jaccard
Journal: Blood
Blood (2020) 135 (18): 1531–1540.
https://doi.org/10.1182/blood.2019004369
Published: 2020
Includes: Supplemental data
Journal Articles

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Clinical Trials & Observations
Christoph R. Kimmich, Tobias Terzer, Axel Benner, Tobias Dittrich, Kaya Veelken, Alexander Carpinteiro, Timon Hansen, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Stefan Wörner, Jörg Beimler, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. Schönland
Journal: Blood
Blood (2020) 135 (18): 1517–1530.
https://doi.org/10.1182/blood.2019003633
Published: 2020
Includes: Supplemental data
Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-6.
https://doi.org/10.1182/blood-2019-132629
Published: 2019
Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, Ellen van der Spek, MD PhD, Roel J.W. Van Kampen, MD PhD, Maaike Sohne, MD, Noortje Thielen, MD PhD, Yavuz Bilgin, MD PhD, Esther G.M. De Waal, MD, Inge Ludwig, MD MSc, Maria B.L. Leijs, MD, Alain Kentos, MD, Gert Jan Timmers, MD PhD, Koen de Heer, MD, Matthijs Westerman, MD, Marie Christiane Vekemans, Nazik Durdu-Rayman, MD, Nicole C.H.P. van der Burg-de Graauw, MD, Niels W. C. J. Van De Donk, MD PhD, Pieter Sonneveld, Saskia K. Klein, MD PhD, Mark-David Levin, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 695.
https://doi.org/10.1182/blood-2019-121694
Published: 2019
Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Peter M. Voorhees, MD, Jonathan L. Kaufman, MD, Jacob P. Laubach, MD, Douglas W. Sborov, MD MSc, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, MD, Rebecca W. Silbermann, MD, Luciano J. Costa, MD PhD, Larry D. Anderson, MD PhD, Nitya Nathwani, MD, Nina D. Shah, MD, Yvonne A. Efebera, MD MPH, Caitlin L. Costello, MD, Andrzej Jakubowiak, MD PhD, Tanya M. Wildes, MD, Robert Z. Orlowski, MD PhD, Kenneth H. Shain, MD PhD, Andrew J. Cowan, MD, Sean Murphy, Yana Lutska, PharmD, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Carla de Boer, Daniela Hoehn, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 691.
https://doi.org/10.1182/blood-2019-123465
Published: 2019
Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Philippe Moreau, MD, Sonja Zweegman, Aurore Perrot, MD PhD, Cyrille Hulin, MD, Denis Caillot, MD, Thierry Facon, MD, Xavier Leleu, MD PhD, Karim Belhadj, Lionel Karlin, MD, Lotfi Benboubker, MD, Mark-David Levin, MD PhD, Monique C. Minnema, MD PhD, Bastien Jamet, Caroline Bodet-Milin, Pieter Sonneveld, Jérôme Lambert, Lixia Pei, Carla de Boer, Jessica Vermeulen, MD PhD, Tobias Kampfenkel, MD, Francoise Kraeber-Bodere
Journal: Blood
Blood (2019) 134 (Supplement_1): 692.
https://doi.org/10.1182/blood-2019-123143
Published: 2019
Journal Articles

Perceptions of Community Hematologists/Oncologists on the Potential of Data Presented at ASH 2018 and ASCO 2019 to Alter the Standard of Care for Multiple Myeloma Treatment

Ajeet Gajra, MD FACP, Richard Sweat, PhD, Yolaine Jeune-Smith, PhD, Bruce Feinberg, DO
Journal: Blood
Blood (2019) 134 (Supplement_1): 5822.
https://doi.org/10.1182/blood-2019-129502
Published: 2019
Journal Articles

Multiple Myeloma :Trends in Consulting Fees and Drug Utilization

Daniel Chakos, MD, Azam Farooqui, MD, Kimberly McCormick, Abhishek R Chilkulwar
Journal: Blood
Blood (2019) 134 (Supplement_1): 5823.
https://doi.org/10.1182/blood-2019-132036
Published: 2019
Journal Articles

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Karrune Woan, MD PhD, Frank Cichocki, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Jason Dinella, PhD, Lauren Fong, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 133.
https://doi.org/10.1182/blood-2019-131138
Published: 2019
Journal Articles

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Lisa C. Holthof, MSc, Hilma J. Van Der Horst, MSc, Renée Poels, Jort T. van der Schans, MSc, Anne T. Gelderloos, MSc, Fengzhi Li, Henk Lokhorst, MD PhD, Sonja Zweegman, MD PhD, Maria Themeli, MD PhD, Niels W. C. J. Van De Donk, Richard W.J. Groen, PhD, Tuna Mutis, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 137.
https://doi.org/10.1182/blood-2019-125818
Published: 2019
Journal Articles

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

John Daly, MSc, Subhashis Sarkar, PhD, Alessandro Natoni, PhD, Robert Henderson, MB BCh, Dawn Swan, Mattias Carlsten, MD PhD, Michael E O'Dwyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 138.
https://doi.org/10.1182/blood-2019-126613
Published: 2019
Journal Articles

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Luciano J. Costa, MD PhD, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María-Victoria Mateos, Enrique M. Ocio, Paula Rodríguez-Otero, Jesús San-Miguel, Shaoyi Li, Rafael Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege, William I. Bensinger
Journal: Blood
Blood (2019) 134 (Supplement_1): 143.
https://doi.org/10.1182/blood-2019-122895
Published: 2019
Journal Articles

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Emad Ibrahim, MBBCh, MD, Anusha Vallurupalli, MBBS, Elizabeth H. Cull, MD, Damian J. Green, MD, Kate Oliver, BS, Jarrod Longcor
Journal: Blood
Blood (2019) 134 (Supplement_1): 144.
https://doi.org/10.1182/blood-2019-131014
Published: 2019
Journal Articles

Targeting Bcl-2 and CD38 As Part of Personalized HSCT Conditioning Regimen in Chemorefractory Acute Leukemia in Children

Larisa Shelikhova, MD, Rimma Khismatullina, MD, Michael Maschan, MD MSc, Alexey A. Maschan, MD, Irina Kalinina, MD, Elena Kurnikova, Yakov Muzalevsky, Alexey Kazachenok, Dmitriy Pershin, Alexander Popov, MD PhD, Galina Novichkova, MD PhD, Dmitriy Balashov, MD PhD, Daria Shasheleva, MD, Svetlana Kashpor, Evgeny Gluhanyuk
Journal: Blood
Blood (2019) 134 (Supplement_1): 150.
https://doi.org/10.1182/blood-2019-129765
Published: 2019